我要投票 九州通在减肥药行业中的票数:200
· 外 推 电 报 ·
2025-01-22 18:10:59 星期三

【九州通是哪个国家的品牌?】

九州通是什么牌子?「九州通」是 九州通医药集团股份有限公司 旗下著名品牌。该品牌发源于湖北,由创始人刘宝林在2000期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

九州通医药集团股份有限公司是一家以药品、医疗器械、生物制品、保健品等产品批发、零售连锁、药品生产与研发及有关增值服务为核心业务的大型企业集团。

截至2012年12月31日,九州通医药集团拥有总资产148.04亿元,员工9,148人,下属公司80余家,直营和加盟的零售连锁药店875家。2012年,九州通医药集团实现营业收入295.08亿元,上缴税收近5亿元。

九州通医药集团拥有完善的品种结构和丰富的客户资源,经营品规达160,000多个,上游供货商5,600家,下游客户70,000多家,取得了国内131种药品的全国或区域总经销或总代理资格。至今为止,九州通医药集团已在全国22个省会城市设立了22家省级子公司(大型医药物流中心)、在29个地级市设立了29家地级公司(地区医药物流配送中心)及400多个终端配送点,形成了覆盖全国大部分县级行政区域的物流配送网络。

打造企业核心竞争力,九州通医药集团秉持“技术让服务更卓越”的理念,致力于现代物流技术和信息技术的开发和应用。目前,九州通医药集团是国内唯一具备独立整合物流规划、物流实施、系统集成能力的医药分销企业,并取得了20多项自主知识产权,在现代物流技术和信息技术方面处于国内领先、国际一流的地位,是国内医药行业唯一获得“中国物流改革开放30年旗帜企业”称号的企业。

九州通医药集团具备向上下游客户提供需求解决方案及增值服务的能力,并逐渐将技术增值服务延伸到了上下游产业链,形成了独具特色的物流管理、供应链管理、医院管理三大产品线,可以满足客户对技术的最高要求。

近年来,九州通医药集团曾获得“国家5A级物流企业”、“湖北省最具影响力民营企业”、“湖北省守合同重信用企业”、“中国社会责任感优秀企业”、“全国非公有制企业双强百佳党组织”等多项荣誉。

未来,九州通医药集团将顺应医药市场变革,继续坚持以医药分销为核心业务,以医院纯销、中药材、医疗器械、零售连锁为战略业务,以物流技术营销、电子商务、国际贸易、原料药等为新兴业务的业务组合战略;扩大和完善医药营销网络布局,不断为医药健康产业提供高性价比服务,努力将九州通打造成为中国医药健康产业最佳服务商。

英文翻译:JIUZHOUTONG Pharmaceutical Group Co., Ltd. is a large-scale enterprise group with the core business of wholesale, retail chain, drug production and R & D and related value-added services of drugs, medical devices, biological products, health products and other products. As of December 31, 2012, JIUZHOUTONG Pharmaceutical Group has a total assets of 14.804 billion yuan, 9148 employees, more than 80 subordinate companies, 875 retail chain drugstores directly operated and joined. In 2012, JIUZHOUTONG Pharmaceutical Group achieved an operating revenue of 29.508 billion yuan and turned in tax revenue of nearly 500 million yuan. JIUZHOUTONG Pharmaceutical Group has a complete variety structure and rich customer resources. It operates more than 160000 products, 5600 upstream suppliers and 70000 downstream customers. It has obtained the qualification of national or regional general distribution or general agent of 131 kinds of drugs in China. So far, JIUZHOUTONG Pharmaceutical Group has set up 22 provincial subsidiaries (large pharmaceutical logistics centers) in 22 provincial capitals, 29 prefecture level companies (regional pharmaceutical logistics distribution centers) and more than 400 terminal distribution points in 29 prefecture level cities, forming a logistics distribution network covering most county-level administrative regions of the country. To build the core competitiveness of the enterprise, JIUZHOUTONG Pharmaceutical Group adheres to the concept of "technology makes service more excellent", and is committed to the development and application of modern logistics technology and information technology. At present, JIUZHOUTONG Pharmaceutical Group is the only pharmaceutical distribution enterprise in China that has the ability to independently integrate logistics planning, logistics implementation and system integration, and has obtained more than 20 independent intellectual property rights. It is in the leading position in modern logistics technology and information technology in China and the first-class position in the world. It is the only one in the domestic pharmaceutical industry that has won the title of "30 years banner enterprise of China's logistics reform and opening up" Enterprises. JIUZHOUTONG Pharmaceutical Group has the ability to provide demand solutions and value-added services to upstream and downstream customers, and gradually extends technology value-added services to the upstream and downstream industrial chains, forming a unique logistics management, supply chain management, hospital management three product lines, which can meet the highest requirements of customers for technology. In recent years, JIUZHOUTONG Pharmaceutical Group has won many honors, such as "national 5A level logistics enterprise", "the most influential private enterprise in Hubei Province", "Hubei Province contract abiding and trustworthy enterprise", "China's outstanding enterprise of social responsibility", "national top 100 Party organizations of non-public enterprises". In the future, JIUZHOUTONG Pharmaceutical Group will continue to adhere to the core business of pharmaceutical distribution, the strategic business of hospital pure sales, Chinese herbal medicine, medical devices, retail chain, the business combination strategy of logistics technology marketing, e-commerce, international trade, API and other emerging businesses, expand and improve the layout of pharmaceutical marketing network, and continue to serve the medical health The industry provides cost-effective services and strives to build Jiuzhoutong into the best service provider in China's pharmaceutical and health industry.

本文链接: https://www.waitui.com/brand/02808d9a5.html 联系电话:027*****3017 立即查看

千城特选小程序码

7×24h 快讯

英国政府借款大幅增加,遵守财政规则面临挑战

英国政府2024年12月预算赤字激增,在利率居高不下、经济增长疲软的情况下,英国政府在遵守财政规则方面面临挑战。英国国家统计局周三表示,12月政府支出超过收入178亿英镑(219.9亿美元),赤字比去年同期高出101亿英镑,远高于预算责任办公室预测的142亿英镑。推动这一增长的一个因素是利息支付,比2023年同期高出38亿英镑。(新浪财经)

11分钟前

策源资本旗下基金入股灵童机器人

36氪获悉,天眼查App显示,近日,灵童机器人(上海)有限公司发生工商变更,新增成都策源广益数字经济股权投资基金合伙企业(有限合伙)、成都高新策源共创企业管理咨询合伙企业(有限合伙)为股东,同时注册资本由103万人民币增至约115.9万人民币。灵童机器人(上海)有限公司成立于2022年8月,法定代表人为陆杰,经营范围含智能机器人的研发、智能机器人销售、服务消费机器人销售、人工智能硬件销售、人工智能应用软件开发、数字内容制作服务等。

11分钟前

百万tokens降价至0.8元后,豆包模型毛利率已能达到50%

从多个知情人士处获悉,豆包大模型去年大幅降价后,毛利率依然为正。其中,字节跳动最新推出的豆包大模型1.5,在推理成本优化上取得进一步突破。在火山引擎上售卖API的Doubao-1.5-pro,毛利率仍能达到50%。去年5月,字节跳动正式对外发布豆包大模型。其中,豆包通用模型pro-32k版,模型推理输入价格仅每百万tokens0.8元,而当时市场上同规格模型的定价一般为每百万tokens120元,是豆包模型价格的150倍。(界面)

11分钟前

华林证券:2024年净利同比预增973.03%—1288.62%

36氪获悉,华林证券发布业绩预告,预计2024年归母净利3.4亿元—4.4亿元,同比增长973.03%—1288.62%。公司持续推进科技金融转型战略,财富管理线上业务收入同比大幅增加。自营投资业务积极把握市场机遇,进一步提升配置资产能力,收入大幅增加。此外,公司针对红博会展信托受益权资产支持专项计划仲裁事项,于2023年度计提预计负债约2.28亿元,导致2024年度相关营业外支出同比大幅下降。该笔营业外支出为非经常性损益。

11分钟前

北京君羊商贸有限公司获千万级Pre-A轮融资

36氪获悉,近日,北京君羊商贸有限公司宣布获得腾信投资领投的Pre-A轮千万级融资。公司创始人邵群表示,本轮融资资金主要投入到开拓业务、技术创新和拓宽市场这三大核心领域,同时将投入大量资金用于AI 算法的优化和模型训练。

11分钟前

本页详细列出关于泰尔维亭的品牌信息,含品牌所属公司介绍,泰尔维亭所处行业的品牌地位及优势。
咨询